CN100496483C - Ligustilide cyclodextrin or its derivatives inclusion compound, its preparation method and pharmaceutical formulation - Google Patents
Ligustilide cyclodextrin or its derivatives inclusion compound, its preparation method and pharmaceutical formulation Download PDFInfo
- Publication number
- CN100496483C CN100496483C CNB2005100213032A CN200510021303A CN100496483C CN 100496483 C CN100496483 C CN 100496483C CN B2005100213032 A CNB2005100213032 A CN B2005100213032A CN 200510021303 A CN200510021303 A CN 200510021303A CN 100496483 C CN100496483 C CN 100496483C
- Authority
- CN
- China
- Prior art keywords
- ligustilide
- cyclodextrin
- cyclodextrin derivative
- clathrate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a ligustilide cyclodextrin or its derivatives inclusion compound, which comprises molecular molar ratio of 1:1-10 ligustilide and cyclodextrin or cyclodextrin derivative. The invention also discloses the process for preparing the inclusion compound, which comprises, dissolving the cyclodextrin or cyclodextrin derivatives into water, producing solution with a concentration of 5-80%, charging ligustilide, stirring, ultrasonic oscillating or grinding.
Description
Technical field
The present invention relates to a kind of clathrate, its preparation method and relevant pharmaceutical preparation of medicinal ingredient, particularly relate to a kind of clathrate, its preparation method and relevant pharmaceutical preparation of cyclodextrin derivative of ligustilide.
Background technology
Ligustilide is a kind of water-fast oily matter, and its structure is as follows:
Because of the outer asymmetric pair of key of ring arranged in the ligustilide structure, can be divided into along anti-two kinds of isomers, because the particularity of himself structure, cis-structure is the space advantage conformation, more stable than trans, thereby be about 10 times of (E)-ligustilide at occurring in nature (Z)-ligustilide content in medical material.Pharmacological research shows that ligustilide has stronger pharmacological action to cardio-cerebrovascular, blood circulation and immune system etc.In Chinese patent 200310108859.6, disclose ligustilide and can prevent and treat atherosclerosis.Chinese patent 03123994.3 report cis form ligustilide has good microcirculation improvement effect, can be used for microcirculation disturbance treatment of diseases and prevention, comprise the treatment and the prevention of shock, diabetic complication, cardio-pulmonary function obstacle, disordered brain function and multiple organs failure etc.
Ligustilide can extract from conventional Chinese medicine such as Radix Angelicae Sinensis, Rhizoma Chuanxiong, Cnidium officinale etc. and obtain, and also can obtain by synthetic.Chinese patent 03123994.3 and 92111278.5 and existing document (Hu Changying, Ding Xiaolin, Wuxi Light Industry Univ.'s journal, 2003,9:69) in, report is in various degree all arranged.The application for a patent for invention " a kind of quick method for preparing the high-purity ligustilide " submitted on July 8th, 2005 of the applicant also discloses the approach that a kind of method of utilizing the decompression column chromatography is prepared the high-purity ligustilide simply fast in addition, and what make ligustilide obtains having become reality.
No matter be which kind of disease of treatment, all the employed pharmaceutical preparation of needs without exception has rapid release, reaches the purpose of therapeutic effect rapidly, adopting intravenous drip is clinically for the most popular method of acute disease, but, it can only be made simply soft capsule for orally using because ligustilide is oiliness.Therefore if ligustilide will be made injection, must at first solve its water-fast problem.
Summary of the invention
Purpose of the present invention is exactly in order to overcome the above problems, provide a kind of by the clathration of cyclodextrin derivative to ligustilide, improve water solublity and the ligustilide cyclodextrin derivative clathrate of stability and the preparation method of this clathrate of ligustilide, and the pharmaceutical preparation of being made by this clathrate is provided.
For achieving the above object, the present invention has adopted following technical scheme:
The invention discloses a kind of ligustilide cyclodextrin derivative clathrate, described clathrate contains the derivant of ligustilide and cyclodextrin, and the molecule mol ratio of ligustilide and cyclodextrin derivative is 1: 1～10, and described cyclodextrin derivative is meant hydroxypropyl-β-cyclodextrin.
Described ligustilide is cis form ligustilide or the mixed type ligustilide that comprises cis-trans.
The invention also discloses a kind of preparation method of ligustilide cyclodextrin derivative clathrate, described method comprises step:
(1) cyclodextrin derivative is soluble in water, make the weight percent concentration scope at 5～80% solution, described cyclodextrin derivative is meant hydroxypropyl-β-cyclodextrin;
(2) according to the molecule mol ratio of ligustilide and cyclodextrin derivative be 1: 1～10 ratio, in the solution that step (1) obtains, directly add the ligustilide that ligustilide or adding are dissolved in organic solvent, described organic solvent is ethanol, methanol, propanol, isopropyl alcohol, ethylene glycol, propylene glycol, glycerol or acetone, perhaps any two or more mixed solvent wherein;
(3) stirring, sonic oscillation or be ground to the solution clear and do not have oil droplet and exist;
Thereby make liquid ligustilide cyclodextrin derivative clathrate.
If further comprise afterwards the exsiccant step of solution in step (3), then make solid ligustilide cyclodextrin or cyclodextrin derivant clathrate.Drying can be used methods such as lyophilization, spray drying, vacuum drying, convection drying.
Described organic solvent preferred alcohol.
Ginding process disclosed by the invention prepares cyclodextrin clathrate, can grind by hand among the Zai Yan Portland, also can place colloid mill fully to grind.
The invention also discloses the pharmaceutical preparation that makes by above-mentioned ligustilide cyclodextrin derivative clathrate.
Described pharmaceutical preparation comprises liquid dosage forms such as infusion solution, liquid drugs injection, powder pin, oral liquid, syrup, and solid dosage forms such as tablet, capsule, granule, dispersible tablet, oral cavity disintegration tablet.
Above-mentioned liquid ligustilide cyclodextrin derivative clathrate can be directly used in liquid dosage forms such as preparation transfusion, liquid drugs injection, powder pin, oral liquid, syrup; Solid ligustilide cyclodextrin derivative clathrate can be made into solid dosage formss such as tablet, capsule, granule, dispersible tablet, oral cavity disintegration tablet.
Beneficial effect of the present invention is:
Cyclodextrin or cyclodextrin derivative are a kind of ring-type hollow garden tubular constructions, and the centre is the cavity, inside has-CH-and the bonded oxygen atom of glucoside be arranged in cavity inside, be hydrophobicity, outsidely form possess hydrophilic property by the hydrophilic radical hydroxyl.By cyclodextrin or cyclodextrin derivative ligustilide is carried out enclose, the ligustilide molecule is embedded in the tubular structure of cyclodextrin or cyclodextrin derivative molecule, become the clathrate of ligustilide cyclodextrin or cyclodextrin derivative.Following advantage is arranged behind the cyclodextrin inclusion compound ligustilide: dissolubility increases; Stability improves; But liquid medicine powdered; Prevent the composition volatilization; Cover adverse drug abnormal smells from the patient or taste; Regulate drug release rate; Improve bioavailability; Reduce medicine irritation and toxic and side effects etc.Therefore cyclodextrin or cyclodextrin derivative are ideal its deliquescent medicinal enclose materials that improves of ligustilide.
Clathrate inclusion rate height of the present invention, thereby improve the water solublity of ligustilide, and the stability of increase ligustilide, make this active component of ligustilide directly apply to solid, liquid dosage form, solved the shortcoming that the ligustilide water solublity is low, can not be directly used in solid dosage forms, especially injection type with the form of clathrate.
Cyclodextrin or cyclodextrin derivative are the less water solublity pharmaceutic adjuvants of a kind of toxicity, are suitable for making multiple liquid preparation and solid preparation with the ligustilide cyclodextrin or the cyclodextrin derivant clathrate of its preparation.Ligustilide cyclodextrin or cyclodextrin derivant clathrate have good water solubility, characteristics that blood vessel irritation is little, and ligustilide increases greatly through its stability behind the enclose, for next step preparation lays a solid foundation.The ligustilide cyclodextrin clathrate has overcome the shortcoming that ligustilide can not prepare water soluble preparation, owing to improved water solublity, and increased the stability of ligustilide, with the solid preparation of its preparation have that disintegrate is fast, stripping good, stable in properties, characteristics that bioavailability is high, be more conducive to clinical practice.
Description of drawings
Fig. 1 is the chromatogram that detects the enclose degree in the embodiment of the invention 1.
The specific embodiment
Also the present invention is described in further detail in conjunction with the accompanying drawings below by specific embodiment.
Ligustilide used among the following embodiment prepares chemical purity by the inventor through extracted form natural plant or chemosynthesis〉98%.In the specific embodiment of the invention, as inclusion agents, be optimum condition of the present invention with hydroxypropyl-β-cyclodextrin.For technical scheme of the present invention better is described, the spy provides following examples, but the present invention is not limited to this.
Embodiment 1:
(1) preparation ligustilide hydroxypropyl-β-cyclodextrin clathrate
Take by weighing 40g (0.0258mol) hydroxypropyl-β-cyclodextrin and add in the 100ml distilled water, fully stirring and dissolving; After other gets cis form ligustilide 1g (0.0052mol) and adds 2ml dehydrated alcohol dilution, add in above-mentioned hydroxypropyl-β-cyclodextrin solution, magnetic agitation 30 minutes, mixing speed is advisable with not outer the spattering of liquid, observe solution to clear, promptly get liquid ligustilide hydroxypropyl-β-cyclodextrin clathrate.This liquid can be made liquid dosage forms such as liquid drugs injection, oral liquid, syrup.Other gets a part of after aforesaid liquid ligustilide hydroxypropyl-β-cyclodextrin clathrate is distributed into bottle, and lyophilization obtains white lyophilized powder, and is standby.
(2) enclose degree detecting
Because hydroxypropyl-β-cyclodextrin clathrate can not be dissolved in ether, but can be dissolved in ethanol, and the ligustilide on the enclose can stripping in ether in cyclodextrin, therefore whether test selects for use ether to dissolve to detect enclose complete.Get the above-mentioned cyclodextrin clathrate lyophilized powder of 1g and add the 5ml ether, fully after the stirring and dissolving, pour out ether, undissolved clathrate adds the 5ml anhydrous alcohol solution; Other gets 1g ligustilide clathrate lyophilized powder and directly adds the 5ml anhydrous alcohol solution; Get above-mentioned three kinds of liquid from left to right o'clock on a lamellae, press thin layer chromatography condition (petroleum ether-ethyl acetate (10:1); The HF254 plate) launch, the record chromatogram is seen Fig. 1.
Do not have ligustilide in the ether solution as shown in Figure 1, and all have in its corresponding ethanol, the ligustilide that enclose success of the test and adding are described is by the whole enclose of cyclodextrin, and inclusion rate is 100%.
(3) soluble test
Get the above-mentioned ligustilide cyclodextrin clathrate of 1g lyophilized powder and progressively add entry, stir, found that adding 1.7ml water just can make cyclodextrin clathrate all dissolve.Illustrate that the ligustilide cyclodextrin clathrate can reach easy molten state fully in water, its water solublity is fabulous.
(4) clathrate stability contrast test
Get above-mentioned ligustilide clathrate lyophilized powder and pure ligustilide respectively and in 80 ℃ of baking ovens, heat after 18 hours and to take out, accurately respectively again take by weighing two kinds of samples that respectively contain ligustilide 10mg, respectively with methanol constant volume to 25ml, press the HPLC condition and measure.
HPLC condition instrument: Agilent 1100 type chromatograph of liquid (quaternary pump, automatic sampler, DAD detector); Chromatographic column: Hypersil ODS (4.6 * 150mm, 5um); Mobile phase: methanol-5% isopropyl alcohol (60:40); Detect wavelength: 280nm; Flow velocity: 1ml.min-1; Column temperature: 25 ℃.Each sample introduction 10ul of sample measures, and the record chromatogram with external standard method calculating ligustilide relative amount separately, the results are shown in Table 1.
Table 1
| Pure ligustilide sample | Ligustilide clathrate lyophilized powder | |
| Ligustilide content (%) | 67.6 | 82.9 |
Its stability obviously raise than pure ligustilide after ligustilide became clathrate with cyclodextrin inclusion compound as can be seen from Table 1, illustrated that the cyclodextrin inclusion compound preparation is the preparation that is applicable to ligustilide.
Embodiment 2: take by weighing 100g (0.0646mol) hydroxypropyl-β-cyclodextrin and add 150ml distilled water, stirring and dissolving.Other takes by weighing after ligustilide 5g (0.0263mol) adds the 10ml95% ethanol dilution, pour in above-mentioned hydroxypropyl-β-cyclodextrin solution, mixed liquor was with magnetic agitation 30 minutes, mixing speed is advisable with not outer the spattering of liquid, observe solution to clear, concentrate, drying under reduced pressure promptly gets solid ligustilide hydroxypropyl-β-cyclodextrin clathrate.This solid clathrates can be prepared into solid dosage formss such as tablet, capsule by the solid preparation method.
The method described in the embodiment 1 of pressing detects enclose degree, water solublity and the stability etc. of gained clathrate.Record and found that enclose is complete; 1g clathrate lyophilized powder progressively adds 1.9ml water and can all dissolve, and water solublity is fabulous; The also purer ligustilide height of stability.
Embodiment 3: take by weighing 40g (0.0258mol) hydroxypropyl-β-cyclodextrin, pour in the 100ml distilled water stirring and dissolving into; Other takes by weighing cis form ligustilide 0.5g (0.0026mol), pours in above-mentioned hydroxypropyl-β-cyclodextrin solution; Place supersonic generator, sonic oscillation is 20 minutes under 40KHz, observes solution to clear, pours out postlyophilization, promptly gets solid cis form ligustilide hydroxypropyl-β-cyclodextrin clathrate.This solid clathrates can be prepared into solid dosage formss such as granule, dispersible tablet by the solid preparation method.
The method described in the embodiment 1 of pressing detects enclose degree, water solublity and the stability etc. of gained clathrate.Record and found that enclose is complete; 1g clathrate lyophilized powder progressively adds 1.7ml water and can all dissolve, and water solublity is fabulous; The also purer ligustilide height of stability.
Embodiment 4 takes by weighing hydroxypropyl-β-cyclodextrin 400g (0.258mol) and cis form ligustilide 40g (0.210mol) adding distil water 500ml, in the colloid mill of model JM-L50b that Shanghai Wang Quan pump industry company limited is produced, ground 10 minutes, spray drying promptly gets solid ligustilide hydroxypropyl-β-cyclodextrin clathrate.This solid clathrates can be prepared into solid dosage formss such as capsule, dispersible tablet by the solid preparation method.
The method described in the embodiment 1 of pressing detects enclose degree, water solublity and the stability etc. of gained clathrate.Record and found that enclose is complete substantially; 1g clathrate lyophilized powder progressively adds 2ml water and can all dissolve, and water solublity is fabulous; The also purer ligustilide height of stability.
Embodiment 5: indoor in the sterile working, take by weighing 30g (0.0194mol) hydroxypropyl-β-cyclodextrin, and be dissolved in water into 90ml, add 0.1g injection active carbon, heat little boiling 15 minutes, filter decarburization.Take by weighing 1g (0.0053m01) cis form ligustilide, use the 3ml95% dissolve with ethanol, pour in hydroxypropyl-β-cyclodextrin magnetic agitation mixing material 30 minutes, (stirring intensity does not produce to splash with liquid and is advisable) into, when observation liquid clear does not have oil droplet, promptly get cis form ligustilide hydroxypropyl-β-cyclodextrin clathrate solution, its solution moisturizing is crossed 0.22 μ m filter membrane to 100ml, be sub-packed in the cillin bottle of 10ml (2-3ml/ bottle), the lyophilization gland promptly gets freeze-dried powder.
The method described in the embodiment 1 of pressing detects enclose degree, water solublity and the stability etc. of gained clathrate.Record and found that enclose is complete; 1g clathrate lyophilized powder progressively adds 1.7ml water and can all dissolve, and water solublity is fabulous; The also purer ligustilide height of stability.
Embodiment 6: take by weighing 30g (0.0194mol) HP-, pour stirring and dissolving in the 400ml distilled water into, add the 0.5g transfusion and use active carbon, be heated with stirring to 80 ℃, be incubated 15 minutes, filtering decarbonization.Other takes by weighing 1g (0.0053mol) ligustilide, pours in hydroxypropyl-β-cyclodextrin bag, and magnetic agitation 20 minutes, (speed controlling does not outwards produce at liquid and splashes) observes obtaining the inclusion complex in solution that clear does not have the ligustilide oil droplet.Its solution moisturizing adds injection 7-8g sodium chloride to 800ml, surveys PH, and transfers PH=3.5-7 with the hydrochloric acid of 0.05N and the sodium hydroxide of 0.05N, and moisturizing adds 0.1g injection active carbon to 1000ml, stirs 20 minutes.Solution takes off charcoal fill (100ml/ bottle), and pressure sterilizing promptly got sodium chloride ligustilide injection in 115 ℃, 30 minutes.
Embodiment 7: ligustilide hydroxypropyl-β-cyclodextrin clathrate formulations prepared from solutions process is with the forward part of embodiment 6.Other takes by weighing glucose for injection 50g, adds the water stirring and dissolving and makes volume reach 100ml, adds the 0.1g active carbon, heats little boiling 15 minutes, takes off charcoal.Glucose Liquid is poured in the inclusion complex in solution, and moisturizing is transferred PH=4 to 800ml. with hydrochloric acid and the 0.05N sodium hydroxide of 0.05N, and moisturizing adds 0.1g injection active carbon to 1000ml, stirs 20 minutes.Solution carries out coarse filtration, fine straining with filter or sand filtration rod (aperture 1.0 μ m, 0.45 μ m, 0.22 μ m) respectively, fill then, and pressure sterilizing promptly got glucose ligustilide injection in 115 ℃, 30 minutes.
In the foregoing description with hydroxypropyl-β-cyclodextrin as inclusion agents, but the present invention is not limited to this.Known in those skilled in the art, hydroxypropyl-β-cyclodextrin and cyclodextrin or other cyclodextrin derivative, as α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, ethoxy-β-cyclodextrin, dihydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, the glucose ring dextrin, the maltose cyclodextrin, the maltotriose cyclodextrin, carboxymethyl cyclodextrin, similar performances such as sulfoalkyl cyclodextrin, effect is identical in preparation clathrate process, therefore in the foregoing description, inclusion agents hydroxypropyl-β-cyclodextrin also can be replaced by cyclodextrin or above-mentioned arbitrary cyclodextrin derivative of enumerating.Those skilled in the art can be according to above-mentioned disclosure, prepares with cyclodextrin or other cyclodextrin derivative ligustilide clathrate as the similar performance of inclusion agents.
Claims (7)
1, a kind of ligustilide cyclodextrin derivative clathrate, it is characterized in that: contain ligustilide and cyclodextrin derivative, and the molecule mol ratio of ligustilide and cyclodextrin derivative is 1: 1～10, and described cyclodextrin derivative is meant hydroxypropyl-β-cyclodextrin.
2, a kind of ligustilide cyclodextrin derivative clathrate according to claim 1 is characterized in that: described ligustilide is cis form ligustilide or the mixed type ligustilide that comprises cis-trans.
3, a kind of preparation method of ligustilide cyclodextrin derivative clathrate is characterized in that: described method comprises step:
(1) cyclodextrin derivative is soluble in water, make the weight percent concentration scope at 5～80% solution, described cyclodextrin derivative is meant hydroxypropyl-β-cyclodextrin;
(2) according to the molecule mol ratio of ligustilide and cyclodextrin derivative be 1: 1～10 ratio, in the solution that step (1) obtains, directly add the ligustilide that ligustilide or adding are dissolved in organic solvent, described organic solvent is ethanol, methanol, propanol, isopropyl alcohol, ethylene glycol, propylene glycol, glycerol or acetone, perhaps any two or more mixed solvent wherein;
(3) stirring, sonic oscillation or be ground to the solution clear and do not have oil droplet and exist.
4, the preparation method of a kind of ligustilide cyclodextrin derivative clathrate according to claim 3 is characterized in that: also comprise step afterwards in step (3): with the solution drying.
5, the preparation method of a kind of ligustilide cyclodextrin derivative clathrate according to claim 3 is characterized in that: described organic solvent is an ethanol.
6, the pharmaceutical preparation that makes by the described ligustilide cyclodextrin derivative clathrate of claim 1.
7, pharmaceutical preparation according to claim 6 is characterized in that, described pharmaceutical preparation comprises infusion solution, liquid drugs injection, powder pin, oral liquid, syrup, and tablet, capsule, granule, dispersible tablet, oral cavity disintegration tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100213032A CN100496483C (en) | 2005-07-15 | 2005-07-15 | Ligustilide cyclodextrin or its derivatives inclusion compound, its preparation method and pharmaceutical formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100213032A CN100496483C (en) | 2005-07-15 | 2005-07-15 | Ligustilide cyclodextrin or its derivatives inclusion compound, its preparation method and pharmaceutical formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1732923A CN1732923A (en) | 2006-02-15 |
| CN100496483C true CN100496483C (en) | 2009-06-10 |
Family
ID=36075678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100213032A Expired - Fee Related CN100496483C (en) | 2005-07-15 | 2005-07-15 | Ligustilide cyclodextrin or its derivatives inclusion compound, its preparation method and pharmaceutical formulation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100496483C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112273709B (en) * | 2020-10-23 | 2022-05-24 | 湖北中烟工业有限责任公司 | Preparation method of Shiyao angelica extract for perfuming tobacco |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506044A (en) * | 2002-09-06 | 2004-06-23 | 山东绿叶天然药物研究开发有限公司 | Slow-releasing prepn containing volatile oil and its prepn process |
| CN1552702A (en) * | 2003-06-03 | 2004-12-08 | 北京九龙制药厂 | Medicinal use and extraction of cis-ligusticum lactone |
-
2005
- 2005-07-15 CN CNB2005100213032A patent/CN100496483C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506044A (en) * | 2002-09-06 | 2004-06-23 | 山东绿叶天然药物研究开发有限公司 | Slow-releasing prepn containing volatile oil and its prepn process |
| CN1552702A (en) * | 2003-06-03 | 2004-12-08 | 北京九龙制药厂 | Medicinal use and extraction of cis-ligusticum lactone |
Non-Patent Citations (6)
| Title |
|---|
| 川芎、当归混合提取挥发油的包合工艺研究. 郭慧玲等.江西医药，第39卷第3期. 2004 |
| 川芎、当归混合提取挥发油的包合工艺研究. 郭慧玲等.江西医药，第39卷第3期. 2004 * |
| 当归的化学及药理研究进展. 王芳等.中国药房，第14卷第10期. 2003 |
| 当归的化学及药理研究进展. 王芳等.中国药房，第14卷第10期. 2003 * |
| 超临界流体萃取法对川芎挥发油成分的研究. 吴广通等.药学服务与研究，第1卷第1期. 2001 |
| 超临界流体萃取法对川芎挥发油成分的研究. 吴广通等.药学服务与研究，第1卷第1期. 2001 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1732923A (en) | 2006-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7678776B2 (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| CN101053556B (en) | Water soluble coenzyme Q10 hydroxyl-beta-cyclodextrin inclusion compound and its preparation method | |
| JP5294509B2 (en) | Cycloastragenol monoglucoside, process for its production and use as a pharmaceutical composition | |
| JP5103476B2 (en) | Drug composition containing inclusion body of cyclodextrin docetaxel and method for producing the same | |
| JP5087086B2 (en) | Drug composition containing inclusion body of cyclodextrin / paclitaxel and method for producing the same | |
| CN104994841B (en) | The biological degradability microballon that is improved comprising the high molecular anticarcinogen adsorption capacity of anionic property and its preparation method | |
| JP5413998B2 (en) | Inclusion complex of pinocembrin by cyclodextrin or its derivatives | |
| CN1166693C (en) | Butylbenzene phthalein cyclodextrin or cyclodextrin derivative clathrate, its preparation method and application | |
| CN102698283A (en) | Baicalein clathrate and preparation method thereof | |
| CN101095670A (en) | Luteolin phospholipid complexes and method for preparing the same and application thereof | |
| JP2011051938A (en) | Highly absorbable drug composition and method for producing the same | |
| JP2812909B2 (en) | Process for the preparation of a flavonol-lignan preparation, a preparation of this kind, a medicament containing the preparation and a process for producing the medicament | |
| CN103211825A (en) | Novel celecoxib composition and preparation process thereof | |
| CN100496483C (en) | Ligustilide cyclodextrin or its derivatives inclusion compound, its preparation method and pharmaceutical formulation | |
| CN102992988A (en) | Substituted phloroglucinol derivatives and application thereof | |
| KR20170095913A (en) | Silybin injection and preparation method therefor | |
| CN102266568A (en) | Preparation method for hydroxypropyl cyclodextrin inclusion of taxol | |
| CN107007839A (en) | A kind of isocorydine inclusion compound and preparation method thereof | |
| CN104162167A (en) | Tamibarotene cyclodextrin or cyclodextrin derivative clathrate and preparation method thereof | |
| CN103083370B (en) | Novel application of total flavones of hippophae rhamnoides | |
| CN102688248B (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN101574525A (en) | Hydroxypropyl-beta-cyclodextrin inclusion compound for lipophilic medicaments, and preparation method thereof | |
| CN1202817C (en) | Solid disperser of quick-releasing vitamine A acid | |
| CN102600084A (en) | Rubescensin-galactosylation chitosan nano particle preparation and preparation method thereof | |
| CN101417005B (en) | Gentian bitterness concealing technique in oral liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090610 Termination date: 20130715 |